CIK 0001583771 · Non-accelerated filer<br>Smaller reporting company
Hepion Pharmaceuticals, Inc.
Sign in to watch- Tickers
- HEPA CTRVP
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 462783806
- Phone
- 732-902-4000
- Business address
- 34 SHREWSBURY AVE., SUITE 1D, RED BANK, NJ, 07701
- Former names
- ContraVir Pharmaceuticals, Inc.
Securities
- HEPA Common stock OTC
- CTRVP Common stock OTC
- Open-market buys, last 90 days
- $10,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$10,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 28 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-03 | Cavan John T Chief Financial Officer | Grant or award · Stock Options | +215,000 | 221,059 | ||
| 2019-07-24 | Cavan John T Chief Financial Officer | Grant or award · Stock Options | +5,820 | 6,059 | ||
| 2019-07-24 | JACOB GARY S Director | Grant or award · Stock Options | +970 | 2,729 | ||
| 2019-07-24 | BRANCACCIO JOHN P Director | Grant or award · Stock Options | +970 | 1,275 | ||
| 2019-07-24 | Block Timothy M. Director | Grant or award · Stock Options | +970 | 1,220 | ||
| 2019-07-24 | ADAMS THOMAS PHD Director | Grant or award · Stock Options | +970 | 1,051 | ||
| 2019-07-24 | Foster Robert T CEO and CSO | Grant or award · Stock Options | +9,700 | 9,879 | ||
| 2019-07-24 | Lippa Arnold Director | Grant or award · Stock Options | +970 | 1,109 | ||
| 2018-07-03 | JACOB GARY S Director | Purchase · Series C Convertible Preferred Stock | +15 | $1,000.00 | $15K | 15 |
| 2018-07-03 | JACOB GARY S Director | Purchase · Warrants | +8,625 | $1,000.00 | $8.6M | 8,625 |
| 2018-07-03 | Cavan John T CFO | Purchase · Series C Convertible Preferred Stock | +15 | $1,000.00 | $15K | 15 |
| 2018-07-03 | Cavan John T CFO | Purchase · Warrants | +8,625 | $1,000.00 | $8.6M | 8,625 |
| 2018-07-03 | Lippa Arnold Director | Purchase · Series C Convertible Preferred Stock | +15 | $1,000.00 | $15K | 15 |
| 2018-07-03 | Lippa Arnold Director | Purchase · Warrants | +8,625 | $1,000.00 | $8.6M | 8,625 |
| 2018-07-03 | BRANCACCIO JOHN P Director | Purchase · Series C Convertible Preferred Stock | +3 | $1,000.00 | $3K | 3 |
| 2018-07-03 | BRANCACCIO JOHN P Director | Purchase · Warrants | +1,725 | $1,000.00 | $1.7M | 1,725 |
| 2018-01-03 | Cavan John T CFO | Grant or award | +101,221 | 167,947 | ||
| 2018-01-03 | SAPIRSTEIN JAMES Chief Executive Officer | Grant or award | +322,092 | 492,819 | ||
| 2018-01-03 | Foster Robert T Chief Scientific Officer | Grant or award | +100,654 | 144,736 | ||
| 2017-07-20 | Cavan John T Chief Financial Officer | Grant or award · Stock Options | +15,000 | 133,688 |
Page 5 of 6 · 119 trades